Trial Profile
A Phase I, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability, food effect and pharmacokinetics of single and repeat doses of FT011 administered orally to healthy volunteers and patients with diabetic nephropathy associated with Type 2 diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs FT 011 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Fibrotech Therapeutics
- 12 Apr 2013 New trial record